Biogen Fully Acquires Biogen Dompé Joint Ventures. Aposense Cancer Drug Demonstrates 100% Oral Bioavailability. Print E-mail
By Staff and Wire Reports   
Tuesday, 06 September 2011 19:48
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 6, 2011.

Biogen Idec Inc (NASDAQ:BIIB) announced it will acquire 100% of Dompé shares in its joint ventures in both Italy and Switzerland. This integration is part of Biogen Idec’s and Dompé Group’s broader strategy to focus on each company’s respective core business.

Under the terms of the agreement, the joint ventures will become 100%-owned affiliates of Biogen Idec, giving the company a direct commercial presence in 29 countries. The new affiliate offices will be renamed Biogen Idec Italia and Biogen Idec Switzerland. In addition, the parties have agreed to the assignment of certain outstanding credits held by the Italian joint venture.

Further financial terms were not disclosed. The joint venture collaboration between the two companies began in 1997 as Biogen Dompé in Italy and Switzerland. Initially, the joint ventures were responsible for the commercialization of AVONEX. They were then expanded to include commercial, distribution and service rights for TYSABRI upon the therapy’s approval in each respective market.


---


Aposense Ltd  (OTC:APNSF) announced ATT-11T, a novel chemotherapy-based cancer drug the Company is developing demonstrated 100% oral bioavailability in a pre-clinical mouse study. Bioavailability is a measure of the amount of a drug that reaches blood circulation following administration.

ATT-11T contains SN-38, the active ingredient in the marketed drug irinotecan, which is administered intravenously. The full oral bioavailability demonstrated by ATT-11T in animals and the impressive results in pre-clinical efficacy and pharmacokinetic studies demonstrate the potential of this compound and position it favorably for further development," said Yoram Ashery, CEO of Aposense.

"Irinotecan (a prodrug of the topoisomerase I inhibitor, SN-38) is a highly potent chemotherapy against solid tumors but its use is limited due to serious adverse reactions. The potential for oral administration, combined with improved efficacy and prolonged pharmacokinetics, may help overcome these limitations." In addition to its oncology portfolio, Aposense is collaborating with GlaxoSmithKline (GSK) and Roche who are using the Company's EarliTest for molecular imaging in clinical trials in which the efficacy of new oncological treatments will be tested.

In return, Aposense has the right to access and use the resulting imaging data. These clinical trials will be fully funded by GSK and Roche.



Also Tuesday:



AB Science SA (NYSE-AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today recruitment of the first patient in the phase 3 study of masitinib in primary progressive multiple sclerosis or relapse free secondary progressive multiple sclerosis.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2011 at 2:10 p.m. Eastern Time at the Grand Hyatt Hotel in New York, NY.

Adolor Corporation (NasdaqGM: ADLR) today announced that it has completed its reacquisition from GlaxoSmithKline (GSK) of all rights to Adolor’s FDA-approved product ENTEREG® (alvimopan).

Amgen (NASDAQ: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 8, 2011, at The New York Palace Hotel in New York City, beginning at 10:00 a.m. Eastern Time.

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) is updating the date and time of the Company's presentation at the Stifel Nicolaus Healthcare Conference to Thursday, September 8, 2011 at 4:25 p.m. EDT (1:25 p.m. PDT).

Anika Therapeutics, Inc. (Nasdaq: ANIK) a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today announced that President and Chief Executive Officer Dr. Charles H. Sherwood will present at the Rodman & Renshaw Annual Global Investment Conference in New York City.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Martin J. Duvall to the position of senior vice president, commercial operations, reporting to the chief executive officer.

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced positive preliminary results from its Phase 1 study assessing the pharmacokinetics of a BEMA Buprenorphine/Naloxone formulation.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Baird 2011 Health Care Conference in New York on Wednesday, September 7th, at 10:00 a.m. EDT, and the Morgan Stanley 2011 Global Healthcare Conference in New York on Tuesday, September 13th, at 10:20 a.m. EDT. Management will present an overview of Charles River’s strategic focus and business developments.

Dyax Corp. (NASDAQ:DYAX)
, a developer of novel biotherapeutics for unmet medical needs, announced today that executive management will present at two investor conferences in September, providing a corporate update regarding the Company’s three major business franchises and value drivers.

Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that its presentation at the Kaufman Bros. 14th Annual Investor Conference to be held on September 7-8, 2011, at the W Hotel New York has been rescheduled to a different time.

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX)
today announced successful results from its Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, an investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced positive results from a Phase I U.S. clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia.

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), announced today that Idenix management will present a corporate overview at the Morgan Stanley Global Healthcare Conference on September 13 at 8:35 a.m. ET at the Grand Hyatt, New York City and at the Bank of America Merrill Lynch Global Healthcare Conference on September 16, 2011 at 8:55 a.m. GMT at the Bank of America Merrill Lynch Financial Centre, London.

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today the appointment of Carole Ben-Maimon, M.D. as president of Global Pharmaceuticals, the Company’s generic pharmaceutical division.

Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has expanded its scientific advisory board with the appointment of two prominent leaders in the fields of vaccines and cancer immunotherapeutics.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2011 at 1:35 p.m. Eastern Time at the Grand Hyatt New York in New York City.

MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 10:00 AM (ET) at the Waldorf-Astoria in New York, New York.

MELA Sciences (NASDAQ: MELA)
today announced that it received CE Mark approval for MelaFind®, allowing the company to market its MelaFind device to dermatologists across the European Union (EU).

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 14, 2011 at 10:20 a.m. ET.

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the UBS Global Life Sciences Conference on Monday, September 19, 2011, at 2:00 pm Eastern Time at the Grand Hyatt Hotel in New York.

Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today the successful completion of the initial cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes.

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2011 will be released after the market close on Monday, September 12, 2011, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,998,991, entitled “Neurotherapeutic treatment for sexual dysfunction.”

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that William F. Owen, Jr., M.D. and David Y. Norton have been elected to the Company's Board of Directors, effective September 1, 2011.

Spherix Incorporated (NASDAQ: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that Dr. Claire Kruger, Chief Executive Officer, and Dr. Robert Lodder, President, will be presenting a corporate overview at the Rodman & Renshaw 13th Annual Healthcare Conference at 3:40 p.m. on September 12, 2011, in Metropolitan West of the Waldorf Astoria in New York.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13 at 11:15 a.m. (ET) in New York.

ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal fourth quarter and full year ended June 30, 2011, on Monday, September 12, 2011.

Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 8,014,952 entitled " Serum Biomarkers in Lung Cancer " to the Company.

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has appointed Caesar J. Belbel, Executive Vice President, Chief Legal Officer and Secretary of the Company.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter